CD 47: New peptide-based drug with anti-angiogenic properties
Description
TAX2 is a new peptide-based drug with anti-angiogenic properties, designed through innovative interdisciplinary approaches (bioinformatics, molecular modeling, biochemical and molecular biology).
The peptide has specific antagonistic properties of the interaction thrombospondin-1 (TSP-1):CD47, which has many pharmacological and therapeutic consequences.
Benefits:
- Anti-angiogenic activity
- A strong anti-tumor and anti-metastatic potential
- Side-effects reduction:
- More continuous and moderate anti-angiogenic response: reduction of thrombosis, stroke and embolism
- No vascular alteration in other organs (brain, lungs) whereas existing drugs cause significant damage
- TAX2 is active in various tissues (pancreas, melanoma, ovarian, lung)
- This receptor is a new target leading to a therapeutic alternative
Sheet
Download the offer